Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T cell therapy for patients with advanced ovarian cancer
2015-000530-30Phase 2Completed
- Sponsor
- Center for Cancer Immune Therapy
- Start
- Apr 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in High-Grade Serous Ovarian Cancer (HGSOC), sponsored by Center for Cancer Immune Therapy. Primary endpoint: Toxicity. Started Apr 2015; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on 2015-000530-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000530-30.